Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Down 10.0% in July

Benitec Biopharma Inc. (NASDAQ:BNTC) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 83,100 shares, a decrease of 10.0% from the June 30th total of 92,300 shares. Based on an average daily volume of 41,800 shares, the days-to-cover ratio is currently 2.0 days. Approximately 3.7% of the shares of the company are sold short.

Benitec Biopharma Stock Down 2.3 %

NASDAQ:BNTC traded down $0.21 during trading hours on Tuesday, reaching $8.90. 39,641 shares of the company were exchanged, compared to its average volume of 54,326. Benitec Biopharma has a 1-year low of $1.86 and a 1-year high of $10.88. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $8.32 and a 200 day moving average of $6.34.

Benitec Biopharma (NASDAQ:BNTC) last released its earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. On average, equities research analysts anticipate that Benitec Biopharma will post -6.56 EPS for the current year.

Institutional Investors Weigh In On Benitec Biopharma

An institutional investor recently raised its position in Benitec Biopharma stock. Janus Henderson Group PLC lifted its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 244,491 shares of the biotechnology company’s stock after buying an additional 64,092 shares during the quarter. Janus Henderson Group PLC owned about 9.44% of Benitec Biopharma worth $1,266,000 at the end of the most recent reporting period. Institutional investors own 52.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BNTC. JMP Securities upped their target price on Benitec Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a research report on Monday, April 22nd. Leerink Partnrs raised Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Piper Sandler initiated coverage on Benitec Biopharma in a research report on Thursday, June 13th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, SVB Leerink initiated coverage on Benitec Biopharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $13.00 price target on the stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.